TI
KPTI icon

Trexquant Investment’s Karyopharm Therapeutics KPTI Stock Holding History

Trexquant Investment’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.84M Sell
188,368
-69,535
-27% -$603K 0.01% 1231
2026
Q1 		$1.44M Buy
257,903
+216,170
+518% +$1.65M 0.01% 1112
2025
Q4 		$307K Buy
+41,733
New +$255K ﹤0.01% 1449
2022
Q4 		– Sell
-7,968
Closed -$653K – 1562
2022
Q3 		$653K Buy
7,968
+1,559
+24% +$116K 0.02% 698
2022
Q2 		$434K Buy
6,409
+4,468
+230% +$410K 0.02% 910
2022
Q1 		$215K Sell
1,941
-12,784
-87% -$1.59M 0.01% 1170
2021
Q4 		$1.42M Buy
14,725
+12,312
+510% +$1.23M 0.09% 291
2021
Q3 		$211K Buy
2,413
+777
+47% +$80.7K 0.02% 934
2021
Q2 		$253K Sell
1,636
-641
-28% -$93K 0.02% 796
2021
Q1 		$359K Sell
2,277
-150
-6% -$31.6K 0.03% 667
2020
Q4 		$563K Buy
+2,427
New +$562K 0.06% 401
2020
Q3 		– Sell
-2,843
Closed -$808K – 1383
2020
Q2 		$808K Buy
+2,843
New +$841K 0.06% 480
2019
Q3 		– Sell
-1,127
Closed -$101K – 989
2019
Q2 		$101K Sell
1,127
-539
-32% -$43.3K 0.01% 745
2019
Q1 		$146K Buy
+1,666
New +$185K 0.01% 906
2018
Q3 		– Sell
-783
Closed -$200K – 1074
2018
Q2 		$200K Sell
783
-1,285
-62% -$318K 0.01% 791
2018
Q1 		$416K Buy
+2,068
New +$412K 0.03% 696
2017
Q3 		– Sell
-1,490
Closed -$202K – 911
2017
Q2 		$202K Buy
+1,490
New +$221K 0.06% 668
2017
Q1 		– Sell
-1,934
Closed -$273K – 1202
2016
Q4 		$273K Buy
+1,934
New +$261K 0.04% 687
2016
Q1 		– Sell
-2,660
Closed -$529K – 1050
2015
Q4 		$529K Buy
+2,660
New +$576K 0.05% 660

Other funds holding KPTI

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Trexquant Investment's KPTI Position: Q2 2026 in Review

Trexquant Investment reduced its Karyopharm Therapeutics (KPTI) stake by 27% in Q2 2026, selling an estimated $603K and leaving 188,368 shares worth $1.84M. The position accounts for 0.01% of the portfolio, ranked #1231.

Trexquant Investment first reported a position in KPTI in Q4 2015 and has held it in 19 quarters since. 97 funds tracked by Wall St. Rank hold KPTI as of Q2 2026.

  • Trexquant Investment held 188,368 shares of Karyopharm Therapeutics worth $1.84M as of Q2 2026.
  • Trexquant Investment sold 69,535 Karyopharm Therapeutics shares in Q2 2026, an estimated $603K.
  • Karyopharm Therapeutics made up 0.01% of Trexquant Investment's portfolio in Q2 2026, its #1231 holding.
  • Trexquant Investment first reported a position in Karyopharm Therapeutics in Q4 2015 and has held it in 19 quarters since.
  • 97 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2026.

Based on Trexquant Investment's 13F filing for Q2 2026, filed 14 Aug 2026.